ReviewDrug design, development and therapy2025
Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic Pathways Linking Type 2 Diabetes Mellitus, Hypertension, and Osteoarthritis to Falls in Older Adults: A Scoping Review.Healthcare (Basel, Switzerland) · 2026Review
- From mechanisms to management: a comprehensive review of sarcopenia in gastric cancer.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human life expectancy increases with social development, which poses problems related to rapid population ageing. As a common disease among the elderly, the prevention and control of diabetes is an ongoing challenge. Diabetes is associated with decreased bone mineral density, increased incidence of fractures, and decreased muscle strength. Meanwhile, the effects and mechanisms of different hypoglycemic drugs on musculoskeletal health vary. Currently, there are limited studies on the effects of anti-diabetic drugs on musculoskeletal health. However, it is necessary to take into account the effect of each hypoglycemic agent, alone or in combination, on musculoskeletal health when determining an individualized treatment approach. Medications that further negatively affect musculoskeletal health should be avoided in specific patients (eg thiazolidinediones and sodium-glucose cotransporter-2 inhibitors). At the same time, some hypoglycemic drugs can be used as potential targets for developing new therapies for osteoporosis/sarcopenia (eg metformin and glucagon-like peptide-1 receptor agonists). The aim of this review is to describe the effects and potential mechanisms of anti-diabetic drugs on musculoskeletal health, including metformin, insulin secretagogues, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors. This review will contribute to the choice of appropriate hypoglycemic drugs to maintain musculoskeletal health in patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.